Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease.
1. A method for generating a monoclonal antibody that binds to and neutralizes two or more strains of an Influenza A virus of the H1 or H3 subtype, comprising (i) administering two, three, four or more immunogenic compositions to a non-human subject, with the administration of each immunogenic composition separated by a certain amount of time, and (ii) generating B-cell hybridomas from the subject and selecting for hybridoma clones that produce a monoclonal antibody that binds to and neutralizes two or more strains of an Influenza A virus of the H1 or H3 subtype, wherein each immunogenic composition comprises an inactivated Influenza virus having a hemagglutinin (HA) polypeptide of the H1 or H3 subtype, an attenuated Influenza virus having an HA polypeptide of the H1 or H3 subtype, a live Influenza virus having an HA polypeptide of the H1 or H3 subtype other than an attenuated Influenza virus having an HA polypeptide of the H1 or H3 subtype, an HA polypeptide or fragment thereof derived or obtained from an Influenza A virus of the H1 or H3 subtype, or a nucleic acid encoding an HA polypeptide or fragment thereof derived or obtained from an Influenza virus of the H1 or H3 subtype, and wherein one immunogenic composition differs from another immunogenic composition in that the HA polypeptide of the H1 or H3 subtype of the Influenza virus, the HA polypeptide of the H1 or H3 subtype or fragment thereof, or the HA polypeptide of the H1 or H3 subtype or fragment thereof encoded by the nucleic acid are antigenically distinct.
2. The method of claim 1 which further comprises isolating the monoclonal antibody.
3. A method for generating a monoclonal antibody that binds to and neutralizes two or more strains of an Influenza A virus of the H1 or H3 subtype comprising: (i) administering to a non-human subject a first immunogenic composition comprising an inactivated first Influenza virus having an HA polypeptide of the H1 or H3 subtype, an attenuated first Influenza virus having an HA polypeptide of the H1 or H3 subtype, a live first Influenza virus having an HA polypeptide of the H1 or H3 subtype other than an attenuated Influenza virus, an HA polypeptide or fragment thereof derived or obtained from a first Influenza virus having an HA polypeptide of the H1 or H3 subtype, or a nucleic acid encoding an HA polypeptide or fragment thereof derived or obtained from a first Influenza virus having an HA polypeptide of the H1 or H3 subtype; (ii) after a first period of time, administering to the subject a second immunogenic composition comprising an inactivated second Influenza virus having an HA polypeptide of the H1 or H3 subtype, an attenuated second Influenza virus having an HA polypeptide of the H1 or H3 subtype, a live second Influenza virus having an HA polypeptide of the H1 or H3 subtype other than an attenuated Influenza virus, an HA polypeptide or fragment thereof derived or obtained from a second Influenza virus having an HA polypeptide of the H1 or H3 subtype, or a nucleic acid encoding an HA polypeptide or fragment thereof derived or obtained from a second Influenza virus having an HA polypeptide of the H1 or H3 subtype, wherein the HA polypeptide of the H1 or H3 subtype of the second Influenza virus is antigenically distinct from the HA polypeptide of the H1 or H3 subtype of the first Influenza virus; (iii) after a second period of time, administering to the subject a third immunogenic composition comprising an inactivated third Influenza virus having an HA polypeptide of the H1 or H3 subtype, an attenuated third Influenza virus having an HA polypeptide of the H1 or H3 subtype, a live third Influenza virus having an HA polypeptide of the H1 or H3 subtype other than an attenuated Influenza virus, an HA polypeptide or fragment thereof derived or obtained from a third Influenza virus having an HA polypeptide of the H1 or H3 subtype, or a nucleic acid encoding an HA polypeptide or fragment thereof derived or obtained from a third Influenza virus having an HA polypeptide of the H1 or H3 subtype, wherein the HA polypeptide of the H1 or H3 subtype of the third Influenza virus is antigenically distinct from the HA polypeptide of the H1 or H3 subtype of the first and the second Influenza viruses; (iv) after a third period of time, administering to the subject a fourth immunogenic composition comprising an inactivated fourth Influenza virus having an HA polypeptide of the H1 or H3 subtype, an attenuated fourth Influenza virus having an HA polypeptide of the H1 or H3 subtype, a live fourth Influenza virus having an HA polypeptide of the H1 or H3 subtype other than an attenuated Influenza virus, an HA polypeptide or fragment thereof derived or obtained from a fourth Influenza virus having an HA polypeptide of the H1 or H3 subtype, or a nucleic acid encoding an HA polypeptide or fragment thereof derived or obtained from a fourth Influenza virus having an HA polypeptide of the H1 or H3 subtype, wherein the HA polypeptide of the H1 or H3 subtype of the fourth Influenza virus is antigenically distinct from the HA polypeptide of the H1 or H3 subtype of the first, second and third Influenza viruses; and (v) after a fourth period of time, generating B-cell hybridomas from the subject and selecting for hybridoma clones that express a monoclonal antibody that binds to and neutralizes two or more strains of an Influenza A virus of the H1 or H3 subtype.
4. The method of claim 3 , wherein the first, second and third periods of time are 2 to 4 weeks or 2 to 6 weeks, and the fourth period of time is 2 to 5 days or 5 to 10 days.
5. The method of claim 3 , wherein the first Influenza virus is A/Hong Kong/1/1968, the second Influenza virus is A/Alabama/1/1981, the third Influenza virus is A/Beijing/47/1992, and the fourth Influenza virus is A/Wyoming/3/2003.
6. The method of claim 3 which further comprises isolating the monoclonal antibody.
7. The method of claim 1 , wherein said non-human subject is a mouse, a rabbit, a rat, a guinea pig, a monkey, or a chimpanzee.
8. The method of claim 3 , wherein said non-human subject is a mouse, a rabbit, a rat, a guinea pig, a monkey, or a chimpanzee.
9. The method of claim 4 , wherein the first, second and third periods of time are 2 to 4 weeks and the fourth period of time is 2 to 5 days.
10. The method of claim 4 , wherein the first, second and third periods of time are 2 to 6 weeks and the fourth period of time is 2 to 5 days.
11. The method of claim 4 , wherein the first, second and third periods of time are 2 to 4 weeks and the fourth period of time is 5 to 10 days.
12. The method of claim 4 , wherein the first, second and third periods of time are 2 to 6 weeks and the fourth period of time is 5 to 10 days.
13. The method of claim 3 , wherein the first, second and third periods of time are 2-8 weeks, 3-4 weeks, 3-5 weeks, 3-7 weeks, 4-6 weeks, 4-8 weeks, 4-12 weeks, or 4-16 weeks; and the fourth period of time is 1-3 days, 2-5 days, 3-7 days, 4-8 days, 5-10 days, or 7-14 days.
14. The method of claim 2 , wherein said monoclonal antibody binds to and neutralizes influenza virus strains A/Hong Kong/1/1968 (H3) virus and A/Panama/2007/1999 (H3).
15. The method of claim 6 , wherein said monoclonal antibody binds to and neutralizes influenza virus strains A/Hong Kong/1/1968 (H3) virus and A/Panama/2007/1999 (H3).
16. The method of claim 2 , further comprising generating a humanized antibody from the isolated monoclonal antibody.
17. The method of claim 6 , further comprising generating a humanized antibody from the isolated monoclonal antibody.
18. The method of claim 1 , wherein the HA polypeptide of the H1 or H3 subtype of the Influenza virus, the HA polypeptide of the H1 or H3 subtype or fragment thereof, or the HA polypeptide of the H1 or H3 subtype or fragment thereof encoded by the nucleic acid of each immunogenic composition are derived from influenza A virus strains of the H1 or H3 subtype that emerged about 5 years, about 10 years, about 20 years, about 25 years, or about 30 years apart from each other.
19. The method of claim 3 , wherein the HA polypeptide of the H1 or H3 subtype of the Influenza virus, the HA polypeptide of the H1 or H3 subtype or fragment thereof, or the HA polypeptide of the H1 or H3 subtype or fragment thereof encoded by the nucleic acid of the first, second, third, and fourth immunogenic compositions are derived from influenza A virus strains of the H1 or H3 subtype that emerged about 5 years, about 10 years, about 20 years, about 25 years, or about 30 years apart from each other.
20. The method of claim 3 , wherein the first Influenza virus is A/South Carolina/1918 (H1), the second Influenza virus is A/USSR/92/77 (H1), the third Influenza virus is A/California/04/09 (H1), and the fourth Influenza virus is A/Brisbane/59/07-like (H1).